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Abstract 
Background: Hyperexcitability of nociceptive afferent fibers is an underlying mechanism of neuropathic pain and 
ion channels involved in neuronal excitability are potentially therapeutic targets. KCNQ channels, a subfamily of 
voltage‑gated K+ channels mediating M‑currents, play a key role in neuronal excitability. It is unknown whether KCNQ 
channels are involved in the excitability of nociceptive cold‑sensing trigeminal afferent fibers and if so, whether they 
are therapeutic targets for orofacial cold hyperalgesia, an intractable trigeminal neuropathic pain.
Methods: Patch‑clamp recording technique was used to study M‑currents and neuronal excitability of cold‑sensing 
trigeminal ganglion neurons. Orofacial operant behavioral assessment was performed in animals with trigeminal 
neuropathic pain induced by oxaliplatin or by infraorbital nerve chronic constrictive injury.
Results: We showed that KCNQ channels were expressed on and mediated M‑currents in rat nociceptive cold‑
sensing trigeminal ganglion (TG) neurons. The channels were involved in setting both resting membrane potentials 
and rheobase for firing action potentials in these cold‑sensing TG neurons. Inhibition of KCNQ channels by linopir‑
dine significantly decreased resting membrane potentials and the rheobase of these TG neurons. Linopirdine directly 
induced orofacial cold hyperalgesia when the KCNQ inhibitor was subcutaneously injected into rat orofacial regions. 
On the other hand, retigabine, a KCNQ channel potentiator, suppressed the excitability of nociceptive cold‑sensing TG 
neurons. We further determined whether KCNQ channel could be a therapeutic target for orofacial cold hyperalge‑
sia. Orofacial cold hyperalgesia was induced in rats either by the administration of oxaliplatin or by infraorbital nerve 
chronic constrictive injury. Using the orofacial operant test, we showed that retigabine dose‑dependently alleviated 
orofacial cold hyperalgesia in both animal models.
Conclusion: Taken together, these findings indicate that KCNQ channel plays a significant role in controlling 
cold sensitivity and is a therapeutic target for alleviating trigeminal neuropathic pain that manifests orofacial cold 
hyperalgesia.
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Background
Many clinical conditions including dental procedures, 
traumatic injury, tumors, and chemotherapy can result 
in chronic trigeminal nerve injury and degeneration [1]. 
These often lead to the development of trigeminal neu-
ropathic pain that manifests as cold allodynia/hyper-
algesia and mechanical allodynia in orofacial regions 
[2, 3]. Cold allodynia/hyperalgesia is a severe pain state 
triggered by innocuous or mild noxious cold tempera-
tures. The trigeminal neuropathic pain constitutes a huge 
health problem because of its severity, special location, 
and resistance to conventional treatment [4]. Therefore, 
there is an imperative need to identify therapeutic targets 
for effectively treating this intractable trigeminal neuro-
pathic pain.
Recent studies have demonstrated that cold stimuli 
are mainly transduced by TRPM8, an ion channel that 
is expressed in both trigeminal ganglion (TG) and dor-
sal root ganglion (DRG) neurons [5, 6]. TRPM8 can 
be activated by cooling temperatures below 28°C and 
also by menthol, an active ingredient of peppermint [5, 
6]. Previous studies by us and others have shown that 
TRPM8 channels are expressed on both non-nociceptive 
and nociceptive cold-sensing neurons, suggesting that 
TRPM8 channels are involved in sensing both innocuous 
and noxious cold under physiological conditions [7, 8]. 
Several electrophysiological differences have been iden-
tified between nociceptive and non-nociceptive cold-
sensing neurons. For example, nociceptive cold-sensing 
neurons express TTX-resistant voltage-gated Na+ chan-
nels; action potentials of these neurons are slow and each 
has a hump in its repolarization phase [9, 10]. On the 
other hand, non-nociceptive cold-sensing neurons only 
express TTX-sensitive voltage-gated Na+ channels and 
they fire fast action potentials without humps [9]. In both 
nociceptive and non-nociceptive cold-sensing neurons, 
TRPM8 starts to be activated at cooling temperatures 
below 28°C [5, 6, 11]. Therefore, there must be mecha-
nisms to prevent nociceptive cold-sensing neurons from 
being excited by innocuous or overexcited by mild nox-
ious cold temperatures under physiological conditions.
KCNQ channels, a subfamily of voltage-gated K+ 
channels activated at low voltages near resting mem-
brane potentials (−50 to −60 mV) [12], may play a role 
in controlling the excitability of nociceptive cold-sensing 
neurons if KCNQ channels are expressed on these sen-
sory neurons. Five KCNQ subunits including KCNQ1 
to KCNQ5 have been identified and 4 of them (KCNQ2-
5) are found to be expressed in the CNS and PNS neu-
rons [12]. DRG neurons are shown to express KCNQ2, 
KCNQ3, and KCNQ5, but functional KCNQ chan-
nels are thought to be mainly KCNQ2/3 heteromeric 
channels and they are believed to underlie the M-type 
outward K+ currents (M-currents) recorded in DRG 
neurons [13–15]. Because they are activated near resting 
membrane potentials, KCNQ channels would counteract 
membrane depolarization and serve as a brake to limit 
membrane depolarization and control neuronal excitabil-
ity. Although this idea has been tested in many CNS neu-
rons and also in some PNS neurons [12], little attention 
has been paid to KCNQ channel’s potential role in con-
trolling the excitability and cold sensitivity of nociceptive 
cold-sensing neurons.
The expression and function of KCNQ channels have 
not been extensively studied in trigeminal ganglion neu-
rons although M-currents were recorded from TG neu-
rons [16]. In DRG neurons, previous studies have shown 
that KCNQ channel subunits KCNQ2 and KCNQ3 are 
expressed in nociceptive DRG neurons and their expres-
sion is down-regulated after nerve injury and in bone 
cancer in animals [13–15, 17]. These studies have fur-
ther shown that the KCNQ channel down-regulation is 
associated with the increase of excitability in nociceptive 
DRG neurons [15, 17]. Unfortunately nociceptive cold-
sensing neurons were not examined in these studies and 
it is currently unknown if these nociceptive neurons 
express KCNQ channels or not. Although TG neurons 
have many functional similarities to DRG neurons, TG 
neurons have properties that distinguish them from DRG 
neurons. For example, 15% of TG neurons were found to 
be TRPM8-expressing cold-sensing neurons, twice the 
percentage of TRPM8-expressing cold-sensing neurons 
in DRGs [5]. Thus, the functions of KCNQ channels in 
cold-sensing TG neurons should be studied directly.
One important advance in research on KCNQ chan-
nels has been the identification of small molecule com-
pounds that can potentiate KCNQ channels [18]. There 
are a series of compounds that can selectively enhance 
KCNQ channel functions, including retigabine, flu-
pirtine, NH6, meclofenamic acid, etc. [18]. Retigabine 
has been shown to be effective in suppressing seizure 
activity in human patients and was recently approved 
for clinical use [19]. Retigabine has also been found to 
potentiate KCNQ channels in DRG neurons and relieve 
carrageenan-induced inflammatory pain in animals 
[13]. However, it is currently unknown whether KCNQ 
channel potentiators can effectively treat cold allodynia/
hyperalgesia.
In the present study, we examined the expression of 
functional KCNQ channels in nociceptive cold-sensing 
TG neurons and determined the roles of these channels 
in controlling the excitability of TG neurons. We also 
evaluated the effect of a KCNQ channel potentiator on 
orofacial cold allodynia/hyperalgesia in animals with 
trigeminal neuropathic pain produced by oxaliplatin or 
infraorbital nerve chronic constrictive injury (ION-CCI).
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Methods
Trigeminal ganglion neuron preparations
Male adult Sprague–Dawley rats (250–350 g) were used. 
Animal care and use conformed to National Institutes 
of Health guidelines for care and use of experimen-
tal animals. Experimental protocols were approved by 
the University of Cincinnati Institutional Animal Care 
and Use Committee. Dissociated trigeminal ganglion 
(TG) neurons were prepared in a manner similar to the 
preparation of dissociated DRG neurons as described 
previously [20]. In brief, rats were deeply anesthetized 
with isoflurane (Henry Schein, NY, USA) and sacrificed 
by decapitation. TGs were rapidly dissected out bilater-
ally in Leibovitz-15 medium (Mediatech Inc. VA, USA) 
and incubated for 1  h at 37°C in minimum essential 
medium for suspension culture (S-MEM) (Invitrogen, 
Grand Island, NY, USA) with 0.2% collagenase and 0.5% 
dispase and then triturated to dissociate neurons. The 
dissociated TG neurons were then plated on glass cover-
slips pre-coated with poly-d-lysine (PDL, 12.5  µg/ml in 
distilled H2O) and laminin (20 µg/ml in Hank’s Buffered 
Salt Solution HBSS, BD bio-science), and maintained in 
MEM culture medium (Invitrogen) that also contained 
nerve growth factor (2.5 S NGF; 10 ng/ml; Roche Molec-
ular Biochemicals, Indianapolis, IN, USA), 5% heat-
inactivated horse serum (JRH Biosciences, Lenexa, KS), 
uridine/5-fluoro-2′-deoxyuridine (10  µM), 8  mg/ml glu-
cose, and 1% vitamin solution (Invitrogen). The dissoci-
ated cells were maintained in an incubator at 37°C with 
a humidified atmosphere of 95% air and 5% CO2. Cells 
were used between 3 and 5 days after the dissociation.
Patch‑clamp recordings from cold‑sensing trigeminal 
ganglion neurons
Coverslips with TG neurons were placed in a 0.5-ml 
microchamber, mounted on an Olympus IX70 inverted 
microscope (Olympus, USA), and continuously perfused 
with a normal bath solution at 2 ml/min. The normal bath 
contained (in mM) 145 NaCl, 5 KCl, 2 MgCl2, 2 CaCl2, 10 
glucose, 10 HEPES, pH 7.3 and osmolarity of 320 mOsm. 
Unless otherwise indicated, bath solution was maintained 
at room temperature of 24°C. Cells were first tested with 
100 μM menthol to pre-identify menthol/cold-sensitive 
cells by using the Ca2+ imaging method which we have 
previously described [21].
For conventional whole-cell recordings, the patch-
clamp electrode internal solution contained (in mM) 
135K-Gluconate, 5 KCl, 2.4 MgCl2, 0.5 CaCl2, 5 EGTA, 
10.0 Hepes, 5.0 Na2ATP, 0.33 GTP-Tris salt, pH was 
adjusted to 7.35 with KOH and osmolarity was adjusted 
with sucrose to 320  mOsm. Recording electrode resist-
ance was 3–6  MΩ, and membrane access resistance in 
the whole-cell configuration was ~10  MΩ and was not 
compensated. Junction potential between bath and elec-
trode solution was calculated to be 17 mV and was cor-
rected for in the data analysis. Voltage-clamp recordings 
were performed with cells held at −60 mV. Signals were 
recorded with an Axopatch 200B amplifier, filtered at 
2 kHz and sampled at 5 kHz using pCLAMP 9.0 (Axon 
Instruments).
Immunohistochemistry
Adult male rats were anesthetized with ketamine/xyla-
zine (100  mg/kg:10  mg/kg, i.p.), transcardially exsan-
guinated with heparinized saline, and perfused with 4% 
paraformaldehyde (PFA) in phosphate buffered saline 
(PBS). TGs were removed and placed in 30% sucrose in 
PBS for overnight cryoprotection. The TGs were then 
embedded in OCT® compound (Baxter Scientific) and 
10 μm sections were cut on a cryostat (Leica Biosystems, 
Buffalo Grove, IL, USA). Sections were thaw-mounted 
onto slides and allowed to air-dry. They were then 
encircled with hydrophobic resin (PAP Pen—The Bind-
ing Site). The slide-mounted sections were incubated at 
room temperature for 30 min in a 4% PFA solution and 
further incubated for 3  h in a mixture solution of 0.4% 
Triton X-100 and 4% PFA. After 3 rinses with PBS, the 
sections were incubated 2  h at room temperature with 
a 2% Triton X-100 solution. The slides were rinsed two 
times with a 1% goat serum PBS and then incubated for 
1 h in a solution of 1:30 normal goat serum in PBS with 
0.4% Triton X-100 to block non-specific antibody bind-
ing. The sections were incubated with a polyclonal rabbit 
anti-KCNQ2 antibody (1:400; Alomone Labs, Jerusalem, 
Israel) over night at 4°C. Following three rinses with 1% 
goat serum PBS solution, the sections were further incu-
bated with a secondary antibody for 3 h at room temper-
ature. The secondary antibody (1:100 in 1% goat serum 
PBS solution) was a goat anti-rabbit IgG conjugated with 
Alexa-488 (Molecular Probes, Eugene, OR, USA). The 
sections were rinsed three times with 1% goat serum PBS 
solution, cover-slipped with a glycerol-based anti-pho-
tobleach medium. Slices were viewed under an inverted 
fluorescent microscope (IX-70, Olympus, Tokyo, Japan).
Orofacial operant behavioral assessment and animal 
models
Behavioral assessments were conducted on male 
Sprague–Dawley rats (300–450  g) as described in our 
previous studies [22, 23]. In brief, animals initially under-
went 4–6 sessions of adaptation trainings in 2  weeks 
using the Ugo Basile Orofacial Stimulation Test System® 
(Comerio VA, Italy). For each training session, animals 
were first fasted for a 12-h period. Each rat was then 
placed in a cage in which there was an Orofacial Stimula-
tion Test System. The Orofacial Stimulation Test System 
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had a drinking window for the rat head to enter and 
acquire a reward (30% sweetened condensed milk, Nestle 
Carnation®). The milk was placed in a cylindrical plas-
tic container with a metal nipple drinker being located 
inside the drinking window. The Orofacial Stimulation 
Test System also consisted of a thermal module with its 
temperature being set at 24°C for training sessions and 
at 17 or 12°C for cold stimulation. An infrared beam was 
built in the drinking window and wired to a computer 
to automatically detect the head accessing the nipple 
drinker. A training session was started by placing a rat 
in the cage. After the rat was given 10  min to familiar-
ize itself with its environment, the drinking window was 
opened and the testing rat was subsequently timed for 
10 min to allow drinking the milk.
After 2 weeks of the adaptation training, the rats were 
entered into two experimental groups, the neuropathic 
pain group induced by oxaliplatin (oxaliplatin group) 
and the trigeminal neuropathic pain group induced by 
infraorbital nerve chronic constrictive ligation (ION-
CCI). For the oxaliplatin group [24], rats were injected 
with oxaliplatin intraperitoneally at a dose of 2  mg/kg 
(200 µl each rat) for five consecutive days (a total dose 
of 10  mg/kg). The controls for the oxaliplatin group 
were rats injected with the same amount of saline. For 
ION-CCI group, right infraorbital nerve of each rat 
was ligated to induce chronic constriction nerve injury 
as described previously [22, 23]. In brief, each rat was 
anesthetized with intraperitoneal injection of ketamine/
xylazine cocktail (100 mg/kg:10 mg/kg). The skin above 
the right eye was shaved and the rat head was immo-
bilized. A 2-cm curvilinear incision was made superior 
to the right orbital cavity. The infraorbital nerve, located 
on the floor of the maxillary bone, was freed from the 
surrounding connective tissues and two ligatures were 
made approximately 5 mm apart with a 5-0 absorbable 
chromic gut suture Superion® [22]. The incision was 
closed with 6-0 non-absorbable braided silk suture. The 
controls were rats with sham surgery without any liga-
tures. During a 2-week healing period, the rats under-
went 2–4 sessions of post-surgical adaption training 
performed in the same manner as the pre-surgical adap-
tation training.
For both oxaliplatin group and ION-CCI group, 1 day 
before the experiments the testing rats’ facial areas were 
shaved. Subsequent experiments were performed for oro-
facial operant tests at the thermal module temperatures 
of 24, 17, or 12°C. The operant tests were performed 
again at these temperatures after injecting retigabine or 
vehicle. Retigabine was administered intraperitoneally at 
the doses of 0.19, 0.59, 1.67 and 15 mg/kg and orofacial 
operant tests were performed between 30 and 120  min 
after retigabine administration.
Data analysis
Whole-cell recording data were analyzed using Clampfit 
9 software. For orofacial operant tests, the events of head 
assessing nipple drinker were detected by the infrared 
beam, recorded by a computer, and analysed by the Oro 
Software (Ugo Basile, Comerio VA, Italy). This computer 
software recorded and analysed several variables of the 
rat’s behaviour including the total time the beam was 
broken, also defined as the total contact time, and the 
total count, which can also be described as total contact 
number. Unless otherwise indicated, total contact time 
in a 10-min experimental session was used as orofacial 
operant behavioural parameters. Data were presented as 
Mean  ±  SEM, analysed by the paired or unpaired Stu-
dent’s t test, *P < 0.05, **P < 0.01, and ***P < 0.001.
Results
In trigeminal ganglion sections, strong immunoreactiv-
ity of KCNQ2 channels (KCNQ2-ir) could be observed in 
some but not all small-sized TG neurons (Fig. 1a). Con-
sistently, patch-clamp recordings made from dissociated 
TG neurons showed the presence of M-type voltage-
gated K+ currents (M-currents) in some small-sized TG 
neurons as demonstrated in Fig. 1b, c. The M-currents in 
TG neurons, as being revealed by the slow deactivating 
tail currents, could be largely inhibited by 20 µM linopir-
dine, a specific blocker of KCNQ channels (Fig.  1b, c). 
Previous studies have shown that only a small percent-
age of TG neurons are TRPM8-expressing cold-sensing 
sensory cells [5]. To determine whether M-currents 
were expressed in cold-sensing TG neurons, we used 
Ca2+-imaging technique to first identify cold-sensing TG 
neurons by testing their sensitivity to menthol, an ago-
nist that activates the cold transducer TRPM8 channels 
(Fig. 1d). Similar to previous studies performed on DRG 
neurons by us and others [9, 11], almost all menthol-sen-
sitive TG neurons were small-sized cells and these cells 
responded to 100  µM menthol by increasing intracellu-
lar Ca2+ levels (Fig.  1d). When patch-clamp recordings 
were applied to these menthol-sensitive TG neurons and 
recordings were performed under the whole-cell current-
clamp mode, these TG neurons could be depolarized and 
fire action potentials following the application of a cold 
temperature ramp from 24 to 8°C (Fig. 1e). Of 36 men-
thol-sensitive TG neurons pre-identified by the Ca2+-
imaging technique, patch-clamp recordings showed that 
15 cells fired slow action potentials. The slow action 
potential had broad action potential width and a hump 
in repolarization phase (Fig. 1f, top panel; Table 1). These 
cells were previously characterized as nociceptive cold-
sensing neurons [9]. The remaining 21 cells showed fast 
action potentials without a hump in action potential 
repolarization phase (Fig.  1f, bottom panel; Table  1). 
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These cells are non-nociceptive cold-sensing neurons 
based on previous studies [9, 10]. Of the 21 non-nocic-
eptive cold-sensing TG neurons, 7 cells (33%) did not 
express detectable M-currents and the remaining 14 
cells (66%) showed M-currents. Overall, the amplitude 
of M-currents, measured by tail currents of deactiva-
tion from −20 to −60 mV, was 46.6 ±  8.9 pA (n =  21) 
in non-nociceptive cold-sensing neurons. In contrast, all 
15 nociceptive cold-sensing TG neurons showed signifi-
cant amounts of M-currents (Fig. 1g, h). The amplitude of 
M-currents was 134.5 ± 24.5 pA (n = 15) in nociceptive 
cold-sensing neurons, significantly higher than M-cur-
rent amplitude of non-nociceptive cold-sensing TG 
neurons (P  <  0.001, Table  1). Nociceptive cold-sensing 
TG neurons also had more negative resting membrane 
potentials and much higher rheobase in comparison 
a b
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Fig. 1 KCNQ channels in nociceptive cold‑sensing trigeminal neurons. a Image shows KCNQ2 immunoreactivity (KCNQ2‑ir) in a trigeminal 
ganglion section. b Sample traces of M‑currents in the absence (black) and presence (red) of 20 µM linopirdine. The voltage step used to reveal 
M‑currents was shown under the recording traces. The box indicates the M‑currents, measured by the tail currents after the voltage step. c I–V curve 
of tail currents in the absence (black) and presence (red) of 20 µM linopirdine. d Ca2+‑imaging shows an example of pre‑identification of cold‑sens‑
ing TG neurons with menthol (100 µM). e An example of a pre‑identified cold‑sensing TG neuron that responded to a cooling temperature ramp by 
firing action potentials. The cell was under the whole‑cell current‑clamp recording mode. The cooling ramp from 24 to 8°C is indicated under the 
recording trace. f Traces on the top panel show a nociceptive cold‑sensing neuron that responds to 10 current‑steps at the increment of 30 pA and 
the cell fires a slow action potential (Rheobase = 300 pA) with broad width and a hump in the repolarization phase. A total of 15 cold‑sensing TG 
neurons belong to this category. Traces on the bottom panel show a non‑nociceptive cold‑sensing neuron that responds to 10 current‑steps at the 
increment of 30 pA and the cell fires a fast action potential (Rheobase = 30 pA) without any hump in the repolarization phase. A total of 21 cold‑
sensing TG neurons belong to this category. g Traces show a nociceptive cold‑sensing neuron that responds to voltage steps from −80 to −20 mV 
at 10 mV increment. The cell was held at −60 mV. h Summary result of M‑currents recorded from nociceptive cold‑sensing neurons in the absence 
(control) and presence of 20 µM linopirdine. The M‑currents were measured by the deactivating tail currents following the voltage step of −20 mV. 
Data represent Mean ± SEM, **P < 0.01.
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with non-nociceptive cold-sensing TG neurons (Fig.  1f; 
Table  1). M-currents of nociceptive cold-sensing neu-
rons were significantly inhibited by 20  µM linopirdine 
(Fig. 1h); the M-current amplitude was 173.6 ± 32.3 pA 
in the absence of linopirdine (n = 9) and 82.2 ± 16.7 pA 
in the present of linopirdine (n = 9, P < 0.01). Similarly, 
M-currents in non-nociceptive cold-sensing TG neurons 
were also significantly inhibited by 20  µM linopirdine 
(Table 1).
Inhibition of M-currents by linopirdine was associ-
ated with a significant reduction (less negative) of rest-
ing membrane potentials in nociceptive cold-sensing 
TG neurons (Fig. 2a, b); the resting membrane potentials 
were −66.9  ±  1.7  mV (n  =  8) in the absence of and 
−60.2  ±  2.0  mV (n  =  8, P  <  0.01) in the presence of 
20 µM linopirdine. This result suggests that KCNQ chan-
nels are involved in setting resting membrane potentials 
in nociceptive cold-sensing TG neurons. Inhibition of 
M-currents by linopirdine also increased the excitability 
of nociceptive cold-sensing TG neurons as was evidenced 
by the significant reduction of the rheobase for evoking 
action potential firing following the application of linopir-
dine (Fig.  2a, c); The rheobase was 660.0  ±  164.0  pA 
(n = 7) before and 381.4 ± 95.9 pA (n = 7, P < 0.05) fol-
lowing the application of 20  µM linopirdine. Nocicep-
tive cold-sensing neurons were much less excitable than 
Table 1 M-currents, resting membrane potentials and rheobase of cold-sensing TG neurons
Data represent Mean ± SEM.
NoCTG nociceptive cold‑sensing trigeminal ganglion neurons, NnCTG non‑nociceptive cold‑sensing trigeminal ganglion neurons, AP action potential, RMP resting 
membrane potential, Cntl control without linopirdine, +Lino in the present of 20 µM linopirdine.
* P < 0.05, ** P < 0.01, *** P < 0.001, ns, no significant difference control vs +Lino, paired Student’s t test; # P < 0.05, ###  P < 0.01, NoCTG group vs NnCTG group, 
unpaired Student’s t test.
AP type M‑current amplitude (pA) RMP (mV) Rheobase (pA)
All cells Cntl +Lino All cells Cntl +Lino All cells Cntl +Lino
NoCTG Slow with 
hump
134 ± 24###, 
n = 15
174 ± 32, 
n = 9
82 ± 17**, 
n = 9
−66 ± 1#, 
n = 15
−67 ± 2, 
n = 8
−60 ± 2**, 
n = 8
426 ± 105###, 
n = 15
660 ± 164, 
n = 7
381 ± 96*, 
n = 7
NnCTG Fast no hump 47 ± 9,  
n = 21
41 ± 10, 
n = 17
18 ± 6***, 
n = 17
−62 ± 1, 
n = 21
−62 ± 1, 
n = 17
−58 ± 2***, 
n = 17
92 ± 17,  
n = 21
101 ± 22, 
n = 17

























































Fig. 2 Increases of the excitability of nociceptive cold‑sensing trigeminal neurons by inhibiting KCNQ channels. a An example shows that block‑
ing KCNQ channels by linopirdine (20 µM) enhances excitability of nociceptive cold‑sensing TG neurons. b Summary of the changes of resting 
membrane potentials (RMP) following the application of 20 µM linopirdine (n = 8). c Summary of the changes of rheobase for action potential firing 
following the application of 20 µM linopirdine (n = 7). d Behavioral cold hypersensitivity induced by linopirdine. Orofacial operant tests were per‑
formed at 12°C following the subcutaneous injection of saline or 0.39 mg linopirdine in oral facial regions. The linopirdine‑injected animals (n = 4) 
show a significant reduction of total contact time in comparison with saline controls (n = 4). Data represent Mean ± SEM, *P < 0.05, **P < 0.01.
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non-nociceptive cold-sensing neurons as was evidenced 
by more than four times higher rheobase (Table 1). In the 
non-nociceptive cold-sensing TG neurons, linopirdine 
also significantly decreased resting membrane potentials 
but rheobase was not significantly changed (Table 1). We 
next determined whether inhibition of KCNQ channels 
may result in behavioral cold hypersensitivity in orofacial 
regions. Linopirdine (0.39  mg, 100  µl) was subcutane-
ously injected into the orofacial regions of rats and oro-
facial operant tests were then performed 20 min later on 
these animals. As shown in Fig. 2d, when tested at 12°C, 
linopirdine injection led to a significant reduction of 
total contact time (265.0 ± 21.0 s with saline injection vs 
62.0 ± 52.4 s with linopirdine injection, n = 4; P < 0.05). 
We then examined whether retigabine, a KCNQ2/3 chan-
nel potentiator, may suppress cold-induced action poten-
tial firing in nociceptive cold-sensing TG neurons. In this 
set of experiments, pre-identified nociceptive cold-sens-
ing TG neurons were recorded under whole-cell current-
clamp mode and action potential firing in these neurons 
was induced by the application of a cold ramp from 24 
to 8°C. As shown in Fig.  3a, b, retigabine (10  µM) sup-
pressed the number of cold-induced action potentials to 
27 ± 4.6% of controls (n = 8, P < 0.01).
Since retigabine suppressed cold-evoked action poten-
tial firing in nociceptive cold-sensing TG neurons, we 
sought to further explore whether the KCNQ2/3 chan-
nel potentiator could be of therapeutic use to alleviate 
trigeminal neuropathic pain that manifests as orofacial 
cold allodynia/hyperalgesia. We utilized two neuropathic 
pain animal models to test this idea. One was the ION-
CCI model, which has been shown to induce cold allo-
dynia/hyperalgesia as demonstrated by using orofacial 
operant tests in our previous studies [22, 23]. The other 
one was oxaliplatin-induced neuropathic pain model 
(oxaliplatin model), which had not been previously char-
acterized using orofacial operant tests. In our oxaliplatin 
model, orofacial operant tests revealed cold allodynia/
hyperalgesia in these animals several days after five con-
secutive injections of oxaliplatin (Fig. 4). Cold allodynia/
hyperalgesia was evidenced by the presence of abnor-
mal operant behaviors in these oxaliplatin-injected ani-
mals, e.g. trying to bite off cold thermal module in order 
to drink milk without getting cold stimulation (Fig.  4a). 
Control animals on the other hand had never behaved 
in such a manner. There was a significant reduction of 
total contact time during the orofacial operant tests per-
formed at cooling temperatures of 17 and 12°C (Fig. 4b, 
d). Significant reduction of total contact time was 
observed 18  days after the injections of oxaliplatin, and 
the effect lasted for about 4  weeks (Fig.  4c). Figure  4d 
shows the comparison between control and oxaliplatin-
injected animals for their total contact time during the 
orofacial operant tests. At cooling temperatures of 17°C 
the total contact time was 121.4 ± 28.6 s (n = 6) in oxali-
platin group, significantly shorter than the control group 
injected with saline (259.3  ±  27.1  s, n  =  5, P  <  0.01). 
More substantial difference in total contact time between 
oxaliplatin group (37.5 ± 14.9 s, n = 8) and control group 
(212.5 ± 15.0 s, n = 8, P < 0.05) was observed at the cool-
ing temperature of 12°C. The very short contact time at 
12°C in oxaliplatin-injected animals indicated that 12°C 
was too noxiously cold to be tolerated by these animals.
We used the oxilaplatin model and orofacial operant 
test to determine whether cold allodynia/hyperalgesia in 































Fig. 3 Suppression by retigabine of cold‑induced action potential firing in nociceptive cold‑sensing trigeminal neurons. a Sample traces show an 
example of cold‑evoked action potential firing in a nociceptive cold‑sensing TG neuron in the absence (control) and presence of 10 µM retigabine. 
Recordings were made under the whole‑cell current‑clamp mode. Cooling temperature ramp was applied from 24 to 8°C as indicated under the 
recording traces. b Summary data shows significant reduction of cold‑evoked action potential firing in nociceptive cold‑sensitive TG neurons 
(n = 8). Action potential numbers are normalized to control value. Data represent Mean ± SEM, **P < 0.01.
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in Fig. 5, the total contact time at the end of 10-min oro-
facial operant test session was 246.4 ± 17.8 s at 24°C and 
37.5 ±  14.9  s at 12°C in rats 3  weeks after oxaliplantin 
injection (n = 8). Administration of vehicle did not sig-
nificantly affect the total contact time at 12°C in these 
oxaliplatin-injected animals. In contrast, the total contact 
time at 12°C after the administration of retigabine was 
dose-dependently increased to 187.6 ± 26.4 s at a dose of 
0.56 mg/kg (n = 8, P < 0.001), 294.5 ± 24.6 s at a dose of 
1.67 mg/kg (n = 8, P < 0.001), and 350 ± 37.5 s at a dose 
of 15 mg/kg (n = 5, P < 0.001). At a low dose of 0.19 mg/
kg, the total contact time at 12°C was 23 ± 5 s (n = 8), 
not significantly different from the total contact time at 
12°C after vehicle injection.
For ION-CCI group, during post-operative period 
of 2–7  weeks, ION-CCI rats consistently showed cold 
Oxa Inj. (17 oC)
Control (17 oC)
0min 1min 2min 4min nim6nim3 nim8nim5 nim01nim7 9min
Control Oxa inj. 



























































Fig. 4 Orofacial operant assessment of oxaliplatin‑induced orofacial cold allodynia/hyperalgesia. a Images show the postures commonly seen 
during orofacial operant tests at 17°C for control rats (left) and rats after oxaliplatin injections (right). The control rat rested its face on the cooling 
module while drinking milk. The oxaliplatin‑injected (18 days after the injections) rat did no contact the cooling thermal module but tried to bite 
it off. b Recordings of contact numbers and duration of each contact in orofacial operant tests at 17°C for the control rat (top) and the oxaliplatin‑
injected rat (bottom). The duration of each orofacial operant test session was 10 min. c Change of total contact time over days after the injections of 
oxaliplatin (n = 5–8). d Left total contact time at 17°C for the rats 18 day after injection of saline (open bar) or oxaliplatin (oxa, closed bar). Right similar 
to left panel except the orofacial operant tests were conducted at 12°C. Data represent Mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001.
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allodynia/hyperalgesia in the orofacial operant tests 
as reported in our previous studies [22, 23]. Similar to 
our previous studies, ION-CCI rats displayed cold allo-
dynial/hyperalgesia as shown in Fig. 4. At 24°C the total 
contact time at the end of 10-min orofacial operant test 
session was 307.2 ±  34.8 (n =  4) for postsurgery base-
line. However, at 12 ◦C the total contact time was sig-
nificantly reduced to 48.9 ±  11.3  s (n =  4, P  <  0.01) in 
these ION-CCI rats. We examined whether cold allo-
dynia/hyperalgesia in ION-CCI rats could be allevi-
ated by retigabine, similar to what was observed in the 
oxaliplatin model. While the total contact time at 12°C 
was not significantly changed following the adminis-
tration of vehicle (62.9 ±  17.9  s, n =  4) or low dose of 
retigabine at 0.19  mg/kg (102.3  ±  24.2  s, n  =  4), the 
total contact time at 12°C was significantly increased to 
206.9 ± 52.9 s (n = 4, P < 0.05) at a dose of 0.56 mg/kg, 
and to 366.5 ± 37 s (n = 4, P < 0.01) at a dose of 1.67 mg/
kg (Fig. 6).
Discussion
In the present study, we show the presence of functional 
KCNQ channels (M-currents) in nociceptive cold-sens-
ing TG neurons and demonstrate their roles in setting 
the excitability and sensitivity of these sensory neurons to 
both electric and cooling stimuli. We further show in our 
in  vivo behavioral experiments using orofacial operant 
tests that inhibition of KCNQ channels directly results in 
behavioral cold hypersensitivity. Furthermore, we dem-
onstrate that potentiation of KCNQ channels alleviates 
cold allodynia/hyperalgesia in both oxaliplatin model 
and ION-CCI model of neuropathic pain. Our findings 
suggest that KCNQ channels may serve as an effective 
therapeutic target for the treatment of trigeminal neu-
ropathic pain that manifests as orofacial cold allodynia/
hyperalgesia.
KCNQ channel appears to be an essential molecule for 
nociceptive cold-sensing TG neurons since all nocicep-
tive cold-sensing TG neurons showed M-currents in our 
study. In contrast, many non-nociceptive cold-sensing 
neurons did not display detectable M-currents. Further-
more, M-currents had higher amplitudes in nociceptive 
cold-sensing TG neurons than in non-nociceptive cold-
sensing TG neurons. The high M-current amplitudes, 
i.e. high KCNQ channel expression, may help maintain 
the low excitability of nociceptive cold-sensing TG neu-
rons to prevent innocuous cold from exciting and mild 
noxious cold from over-exciting these nociceptive neu-
rons under physiological conditions. The expression of 
KCNQ channels was found to be highly regulated and 
previous studies showed that KCNQ channels in nocic-
eptive DRG neurons were down-regulated under neuro-
pathic and inflammatory conditions, which resulted in 
the hyperexcitability of nociceptive DRG neurons [14, 15, 
17]. There is a possibility that KCNQ channels are also 
down-regulated in nociceptive cold-sensing TG neurons 
under pathological conditions, such as trigeminal neu-
ropathy induced by chemotherapy and chronic trigemi-
nal nerve injury and degeneration. A down-regulation of 





















Fig. 5 Alleviation of oxaliplatin‑induced orofacial cold hyperalgesia 
by retigabine. Bar graph shows total contact time of orofacial operant 
tests for oxaliplatin‑injected rats under the following conditions: 24, 
12, 12°C with vehicle injection, 12°C with retigabine treatment at 
the dose of 0.19, 0.56, 1.67, and 15 mg/kg. Retigabine was adminis‑





















Fig. 6 Alleviation by retigabine of orofacial cold hyperalgesia in 
infraorbital nerve chronic constrictive injury model. Bar graph shows 
total contact time of orofacial operant tests for infraorbital nerve 
chronic constrictive injury (ION‑CCI) animals under the following 
conditions: 24, 12, 12°C with vehicle injection, 12°C with retigabine 
treatment at the doses of 0.19, 0.56, and 1.67 mg/kg. Retigabine 
was administrated intraperitoneal to the animals. Data represent 
Mean ± SEM, *P < 0.05; **P < 0.01.
Page 10 of 11Abd‑Elsayed et al. Mol Pain  (2015) 11:45 
would increase the excitability of these cold-sensing neu-
rons, which would lead to trigeminal neuropathic pain 
that manifests as cold allodynia/hyperalgesia. Consist-
ent with this idea, we demonstrated that orofacial cold 
allodynia/hyperalgesia could be induced pharmacologi-
cally by inhibition of KCNQ channels with linopirdine. 
Furthermore, the KCNQ channel potentiator, retigabine, 
alleviated orofacial cold allodynia/hypealgeisa in the 
two neuropathic pain models used in the present study. 
However, the above putative mechanism will need to be 
confirmed by direct evidence showing KCNQ down-
regulation at both protein and functional levels in these 
two animal models. There is another possibility that 
down-regulation of KCNQ did not occur in nociceptive 
cold-sensing TG neurons of our two animal models and 
orofacial cold allodynia/hyperalgesia was mediated by 
other mechanisms. In fact, upregulation of TRPM8 or 
TRPA1 has been previously suggested to be underlying 
mechanisms of cold allodynia/hyperalgesia after nerve 
injury and tissue inflammation [25, 26]. In addition, a 
recent study suggested that down-regulation of TREK1 
and TRAAK potassium channels and up-regulation of 
HCN channels contributed to oxaliplatin-induced cold 
hypersensitivity [27]. Since KCNQ channel activation is 
downstream to cold transduction and membrane excita-
tion, KCNQ channels should still be desirable therapeu-
tic targets for effectively treating allodynia/hyperalgesia 
due to other mechanisms that cause cold hypersensitiv-
ity. Functional KCNQ channels in cold-sensing TG neu-
rons may be KCNQ2/3 channels since KCNQ2-ir was 
detected in small sized TG neurons and KCNQ2/3 chan-
nels were found to be major KCNQ channels in nocicep-
tive DRG neurons. Therefore, in addition to retigabine, 
other KCNQ2/3 channel potentiators may also be useful 
in treating orofacial cold allodynia/hyperalgesia.
We used ION-CCI model in the present study because 
it well represents chronic trigeminal nerve injury seen in 
human patients [22, 23]. We also used oxaliplatin model 
because oxaliplatin is the first line chemotherapy for 
advanced colorectal cancer, but orofacial cold allodynia 
and hyperalgesia are its major side-effects [28]. Orofa-
cial operant tests were used in this study to allow us to 
measure pain rather than nociceptive reflex [22, 29]. 
This is an important advantage over classical behavioral 
tests, and our orofacial operant tests provide clinically 
relevant measures for the therapeutic effects of reti-
gabine. The therapeutic effect of retigabin demonstrated 
in both models and with orofacial operant tests carries a 
great hope for patients with trigeminal neuropathic pain 
due to different causes. Retigabine has been approved 
by FDA for treating epilepsy clinically but it has side 
effects including dizziness and tremor due to its actions 
on KCNQ channels in the CNS. Future development of 
KCNQ potentiators that selectively act on KCNQ chan-
nels in the peripheral nervous system would help to limit 
their side effects.
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